Daniel Soland recently joined the board of directors at ACADIA Pharmaceuticals, Inc., a biopharmaceutical company that focuses on developing and commercializing medicines related to nervous system disorders.
The company has reported positive Phase III study results for NUPLAZID to treat Parkinson’s disease psychosis.
“Dan brings a tremendous wealth of commercial experience to the board, and his perspective and insight will be welcomed as ACADIA advances NUPLAZID toward registration and prepares for the planned launch of NUPLAZID in the United States,” Leslie L. Iversen, chairman of ACADIA’s board of directors, said. “In addition to his extensive commercial experience in launching new drugs and life cycle management, he has led manufacturing and quality organizations, and has been instrumental in driving growth in the companies he has served.”
Soland has more than 30 years of experience in the biopharmaceutical industry. He previously served as the senior vice president and chief operating officer of ViroPharma from 2008 to 2014. From 2006 to 2008, Soland was the vice president and chief commercial officer of the company.
In his positions at ViroPharma, Soland managed the commercial, manufacturing and quality organization; helped create the company’s commercial infrasturucture in the United States, Europe and Canadal; and led the launch of Cinryze, which is used to prevent hereditary angioedema attacks.
Before ViroPharma, Soland served as president of Chiron Vaccines from 2005 to 2006. He also was president and CEO of Epigenesis Pharmaceuticals from 2002 to 2005 and held multiple positions at GlaxoSmithKline from 1993 to 2002.
Alerts Sign-up